Close Menu

NEW YORK – Meridian Bioscience today reported a 6 percent year-over-year decrease in its fiscal third quarter revenues driven primarily by competitive pressures in the diagnostics segment.

The Cincinnati-based life science and diagnostics firm recorded revenues of $48.4 million compared to $51.7 million a year ago, missing analysts' consensus estimate of $49.8 million.

To read the full story....

...and receive Daily News bulletins.

Already have a 360Dx or GenomeWeb account?
Login Now.

Don't have a 360Dx or GenomeWeb account?
Register for Free.

Jan
28
Sponsored by
Sophia Genetics

This webinar will discuss how Moffitt Cancer Center has implemented a new capture-based application to accurately assess myeloid malignancies by detecting complex variants in challenging genes in a single experiment.